Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 42 (50.0%)

Trials by Status

not_yet_recruiting125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_4

Levofloxacin Concomitant Versus Levofloxacin Sequential

NCT06065267
completedphase_4

CANHelp Working Group Treatment Trials

NCT01967329
completedphase_2

Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer

NCT01413828
completedphase_2

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

NCT00532623

Clinical Trials (4)

Showing 4 of 4 trials
NCT06065267Phase 4

Levofloxacin Concomitant Versus Levofloxacin Sequential

Not Yet Recruiting
NCT01967329Phase 4

CANHelp Working Group Treatment Trials

Completed
NCT01413828Phase 2

Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer

Completed
NCT00532623Phase 2

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4